Daniel Curran's most recent trade in Alx Oncology Holdings Inc was a trade of 16,833 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 20, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Alx Oncology Holdings Inc | Daniel Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2026 | 16,833 | 16,833 | - | - | Stock Option (right to buy) | |
| Catalyst Pharma Inc | Daniel Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2025 | 18,115 | 58,115 | - | - | Options to purchase common stock | |
| Catalyst Pharma Inc | Daniel Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2025 | 5,468 | 63,583 | - | - | Restricted Stock Units | |
| Alx Oncology Holdings Inc | Daniel Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2025 | 40,400 | 40,400 | - | - | Stock option (right to buy) | |
| Xilio Therapeutics Inc | Daniel Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 31,000 | 31,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Daniel Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 25,000 | 25,000 | - | - | Stock Option (right to buy) |